Your browser doesn't support javascript.
loading
Should early antiretroviral therapy (CD4 > 350 cells/mm3) vs deferred antiretroviral therapy (CD4 < 350 cells/mm3) be used for prevention of tuberculosis?
World Health Organization; Suthar, A B; Lawn, S D; del Amo, J; Getahun, H; Dye, C; Sculier, D; Sterling, T R; Chaisson, R E; Williams, B G; Harries, A D; Granich, R M.
Geneva; World Health Organization; 2013. (WHO/HIV/2013.21).
in English | WHO IRIS | ID: who-90573
Responsible library: CH1.1
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Databases of international organizations Health context: Sustainable Health Agenda for the Americas / SDG3 - Health and Well-Being / Neglected Diseases Health problem: Goal 9: Noncommunicable diseases and mental health / Target 3.3: End transmission of communicable diseases / Neglected Diseases / Tuberculosis Database: WHO IRIS Main subject: Tuberculosis / HIV Infections / Anti-Retroviral Agents Language: English Year: 2013
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Databases of international organizations Health context: Sustainable Health Agenda for the Americas / SDG3 - Health and Well-Being / Neglected Diseases Health problem: Goal 9: Noncommunicable diseases and mental health / Target 3.3: End transmission of communicable diseases / Neglected Diseases / Tuberculosis Database: WHO IRIS Main subject: Tuberculosis / HIV Infections / Anti-Retroviral Agents Language: English Year: 2013